Randomized, multi-center study comparing prolonged primary systemic endocrine therapy with letrozole alone or in combination with zoledronic acid in early breast cancer (NEOadjuvant Study in CANada).

Trial Profile

Randomized, multi-center study comparing prolonged primary systemic endocrine therapy with letrozole alone or in combination with zoledronic acid in early breast cancer (NEOadjuvant Study in CANada).

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Letrozole (Primary) ; Zoledronic acid (Primary)
  • Indications Early breast cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 12 Nov 2008 Status changed from active, no longer recruiting to completed.
    • 14 Oct 2008 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 07 Dec 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top